Assembly Biosciences Inc (ASMB)
12.95
+0.25
(+1.97%)
USD |
NASDAQ |
May 08, 16:00
13.69
+0.74
(+5.71%)
After-Hours: 18:08
Assembly Biosciences Enterprise Value: -60.62M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | -60.62M |
May 06, 2024 | -59.79M |
May 03, 2024 | -58.15M |
May 02, 2024 | -60.01M |
May 01, 2024 | -57.49M |
April 30, 2024 | -61.88M |
April 29, 2024 | -59.52M |
April 26, 2024 | -60.89M |
April 25, 2024 | -57.00M |
April 24, 2024 | -56.34M |
April 23, 2024 | -57.49M |
April 22, 2024 | -57.76M |
April 19, 2024 | -56.72M |
April 18, 2024 | -57.16M |
April 17, 2024 | -59.41M |
April 16, 2024 | -50.64M |
April 15, 2024 | -48.39M |
April 12, 2024 | -49.92M |
April 11, 2024 | -47.68M |
April 10, 2024 | -49.76M |
April 09, 2024 | -48.83M |
April 08, 2024 | -51.29M |
April 05, 2024 | -54.75M |
April 04, 2024 | -55.46M |
April 03, 2024 | -54.64M |
Date | Value |
---|---|
April 02, 2024 | -56.23M |
April 01, 2024 | -59.52M |
March 28, 2024 | -57.33M |
March 27, 2024 | -56.89M |
March 26, 2024 | -58.64M |
March 25, 2024 | -57.87M |
March 22, 2024 | -59.08M |
March 21, 2024 | -63.36M |
March 20, 2024 | -62.32M |
March 19, 2024 | -65.39M |
March 18, 2024 | -65.55M |
March 15, 2024 | -63.52M |
March 14, 2024 | -64.18M |
March 13, 2024 | -60.94M |
March 12, 2024 | -60.18M |
March 11, 2024 | -56.78M |
March 08, 2024 | -55.79M |
March 07, 2024 | -57.39M |
March 06, 2024 | -57.82M |
March 05, 2024 | -56.50M |
March 04, 2024 | -57.16M |
March 01, 2024 | -56.39M |
February 29, 2024 | -60.12M |
February 28, 2024 | -60.40M |
February 27, 2024 | -62.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-78.96M
Minimum
Dec 03 2021
660.41M
Maximum
Jul 20 2020
66.61M
Average
-17.89M
Median
Jun 24 2022
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 2.560M |
Palatin Technologies Inc | 24.08M |
iBio Inc | 16.84M |
Theriva Biologics Inc | -13.05M |
Oragenics Inc | 4.426M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -10.96M |
Revenue (Quarterly) | 7.163M |
Total Expenses (Quarterly) | 19.71M |
EPS Diluted (Quarterly) | -1.999 |
Profit Margin (Quarterly) | -153.0% |
Earnings Yield | -104.4% |
Normalized Earnings Yield | -104.40 |